We investigated whether 2-chlorodexoyadenosine could induce apoptosis in B cell chronic lymphocytic leukemia (B-CLL) cells in vitro using clinically achievable drug doses, measuring apoptosis ratio by flow cytometry. B cells were isolated from previously untreated patients and apoptosis was measured in these cells immediately after isolation and following incubation in vitro, without and with 2-chlorodeoxyadenosine at different concentrations, for 24 and 48 h. Distribution of cellular DNA content and quantitative analysis of apoptosis were determined by standard propidium iodide staining and flow cytometry. Spontaneous apoptosis occurred in B-CLL cells incubated in vitro in the absence of drug, but the level of apoptosis was greater in cells treated with 2-chlorodeoxyadenosine after the second day of culture. The present in vitro study of B-CLL cells from previously untreated patients suggests this chemotherapeutic agent activates a program of cell death by apoptosis using a drug dose equivalent to the physiological concentration used in patients in vivo. These data reveal an interesting possibility in the 2-chlorodeoxyadenosine treatment of untreated patients by neoplastic B cell apoptosis induction.

Download full-text PDF

Source
http://dx.doi.org/10.1038/sj.leu.2400713DOI Listing

Publication Analysis

Top Keywords

b-cll cells
12
untreated patients
12
cell chronic
8
chronic lymphocytic
8
lymphocytic leukemia
8
apoptosis
8
flow cytometry
8
cells
6
induction apoptosis
4
2-chlorodeoxyadenosine
4

Similar Publications

Chronic lymphocytic leukemia (CLL) can rarely transform into Waldenström macroglobulinemia (WM), posing diagnostic and therapeutic challenges. The diagnosis of WM requires bone marrow infiltration by lymphoplasmacytic cells and the presence of IgM gammopathy. Immunophenotypic markers include FMC7+, CD19+, CD20+, and CD138+.

View Article and Find Full Text PDF

Characterization of TFIIE-regulated genes by transcriptome analysis.

Turk J Biol

October 2024

Faculty of Science, Molecular Biology and Genetics, İhsan Doğramacı Bilkent University, Ankara, Turkiye.

Background/aim: Previous studies on general transcription factor II E (GTF2E) showed that it is associated with certain groups of diseases, such as colon cancer and trichothiodystrophy, but the global effect of GTF2E on cellular processes is still not widely characterized. This study aimed to investigate and characterize the effect of GTF2E on the transcription level of genes and identify the cellular processes and diseases associated with GTF2E.

Materials And Methods: The human colorectal carcinoma cell line HCT116 used in the study was transfected at a 30 nM concentration with siGTF2E1 or nontarget negative siRNA.

View Article and Find Full Text PDF
Article Synopsis
  • The BAG3 protein plays a key role in regulating cell survival and is being studied as a potential target for treating various cancers, particularly B-cell chronic lymphocytic leukemia (B-CLL).
  • Research shows that silencing BAG3 in stromal fibroblasts leads to increased apoptosis in B-CLL cells by disrupting critical survival signaling pathways.
  • The study highlights the link between BAG3 expression, cytokine networks, and tumor survival, suggesting that understanding these interactions could lead to new therapies for CLL.
View Article and Find Full Text PDF

presents a single nucleotide polymorphism at location 158 (V/F), which affects its binding to the fragment crystallizable (Fc) of antibodies (Abs). FcγRIIIa-158 V allotype has the highest affinity and is associated with a better clinical response to IgG1 monoclonal Abs (mAb) treatment. We compared the allele frequency of F158V polymorphism in cohorts of patients with B-cell lymphoproliferative disorders, including multiple myeloma (MM), monoclonal gammopathy of undetermined significance (MGUS), non-Hodgkin lymphoma (NHL), and B-cell chronic leukemia (B-CLL).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!